CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 62 enrolled
Drug / intervention
Pregabalin +2 moredrug
Likely dose
Pregabalin 75 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01094808
NCT01094808Phase 4Completed

Effect of Pregabalin on Colonic Sensorimotor Function in Healthy Adults.

Mayo Clinic·interventional·Posted Mar 29, 2010·Updated Mar 7, 2012

In Brief

A Phase 4 clinical trial evaluating Pregabalin, Placebo, and 1 other intervention for Healthy. Completed, enrolled 62 participants across 1 site.

Detailed Summary

This study is being done to evaluate the effects of pregabalin, a drug approved for anticonvulsive therapy and for neuropathic pain, on colonic and sensory functions in healthy individuals. The specific study hypotheses were as follows: 1) pregabalin increases sensation thresholds, decreases sensation ratings, and increases compliance in response to balloon distension in the colon; 2) pregabalin reduces colonic phasic and tonic motility in response to a standardized meal; and 3) sensation ratings are lower with higher colonic compliance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesUnited States

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 29, 2010
Enrollment StartMar 1, 2010
Primary CompletionFeb 1, 2011
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 16.3 years ago

Interventions

Pregabalindrug

FDA approved medication (capsules) at 75 mg and 200 mg doses

Placebodrug

Placebo capsules

Bowel preparationother

Polyethylene glycol electrolyte solution bowel preparation